Zura Bio Limited (NASDAQ:ZURA) Sees Significant Drop in Short Interest

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) saw a large drop in short interest during the month of April. As of April 15th, there was short interest totalling 2,590,000 shares, a drop of 51.8% from the March 31st total of 5,370,000 shares. Currently, 5.6% of the shares of the company are sold short. Based on an average trading volume of 373,200 shares, the short-interest ratio is currently 6.9 days.

Wall Street Analyst Weigh In

Several analysts have weighed in on ZURA shares. HC Wainwright reiterated a "buy" rating on shares of Zura Bio in a research note on Thursday, April 3rd. Oppenheimer reissued an "outperform" rating and set a $19.00 price target (down from $20.00) on shares of Zura Bio in a research report on Wednesday, March 26th. Guggenheim reiterated a "buy" rating and issued a $15.00 price objective on shares of Zura Bio in a research note on Wednesday, March 26th. Finally, Chardan Capital decreased their target price on shares of Zura Bio from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, March 26th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $14.67.

Zura Bio Stock Performance

Shares of NASDAQ:ZURA remained flat at $1.47 during trading on Friday. 230,943 shares of the stock traded hands, compared to its average volume of 388,371. The business's 50-day simple moving average is $1.28 and its two-hundred day simple moving average is $2.22. Zura Bio has a 52-week low of $0.97 and a 52-week high of $6.35. The stock has a market capitalization of $100.51 million, a P/E ratio of -2.77 and a beta of 0.05.

Zura Bio (NASDAQ:ZURA - Get Free Report) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.09. The firm had revenue of $0.00 million during the quarter. As a group, equities research analysts anticipate that Zura Bio will post -0.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Zura Bio

A number of large investors have recently bought and sold shares of the business. American Century Companies Inc. acquired a new stake in Zura Bio in the fourth quarter valued at approximately $27,000. Prudential Financial Inc. purchased a new stake in Zura Bio in the 4th quarter worth $28,000. Two Sigma Advisers LP acquired a new position in Zura Bio during the fourth quarter worth $32,000. ProShare Advisors LLC acquired a new stake in shares of Zura Bio in the fourth quarter valued at about $35,000. Finally, XTX Topco Ltd purchased a new stake in shares of Zura Bio during the fourth quarter worth about $44,000. Institutional investors and hedge funds own 61.14% of the company's stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.